According to a new report North America Cardiac Biomarkers Testing Market, published by KBV research, the North America Cardiac Biomarkers Testing Market would witness market growth of 10.7% CAGR during the forecast period (2019-2025).
The Myocardial Infarction market dominated the North America Cardiac Biomarkers Testing Market by Application in 2018, growing at a CAGR of 10.2 % during the forecast period. The Congestive Heart Failure market is expected to witness a CAGR of 11.7% during (2019 - 2025). Additionally, The Acute Coronary Syndrome market is expected to witness highest CAGR of 10.1% during (2019 - 2025).
The USA market dominated the North America Point of Care Testing Market by Country in 2018, growing at a CAGR of 7.6 % during the forecast period. The Canada market is expected to witness a CAGR of 8.4% during (2019 - 2025). Additionally, The Mexico market is expected to witness a CAGR of 10.4% during (2019 - 2025).
The Troponins market dominated the Canada Cardiac Biomarkers Testing Market by Type in 2018, thereby, achieving a market value of $235.6 million by 2025, growing at a CAGR of 10.3 % during the forecast period. The Ischemia Modified Albumin market is expected to witness a CAGR of 13.4% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/north-america-cardiac-biomarkers-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Trivitron Healthcare Pvt. Ltd., ABBOTT Laboratories, Siemens AG, Becton, Dickinson AND Company, Bio-Rad laboratories, Inc., Randox Laboratories Limited, Danaher Corporation, Thermo Fisher Scientific, Inc., Johnson and Johnson and Quidel Corporation.
By Type
By Application
By Location of Testing
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
